Cryo-Cell International Inc (CCEL)

AMEX · Healthcare · Medical Care Facilities · USA

Cryo-Cell International Inc is a micro cap company (market value under $300 million) in the Medical Care Facilities industry.

Cryo-Cell International collects and preserves umbilical cord blood and tissue stem cells for families and the public through private and public banking services. The company manufactures the PrepaCyte CB Processing System for processing cord blood stem cells and maintains cryogenic storage facilities in Florida and North Carolina serving newborn families and medical institutions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cryo-Cell International Inc stock.

Our verdict on CCEL

Overvalued: intrinsic value $1.65 per share, market price $4.63, margin of safety -179.9% (as of 2026-11-17).

Discounting its cash flows at 7.5% (average of 2 methods) values the shares at $1.65; the price of $4.63 is 180% above that value, and 81% of that value comes from beyond year five.

ETFs with the most weight in CCEL

More on CCEL

Browse

Peers in Medical Care Facilities

All 48 Medical Care Facilities stocks

Cheaper than CCEL in Medical Care Facilities

24 more in this industry show a wider margin of safety.

Is CCEL undervalued or overvalued?

CCEL is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 7.5% (average of 2 methods) values the shares at $1.65; the price of $4.63 is 180% above that value, and 81% of that value comes from beyond year five.

What is the intrinsic value of CCEL?

$1.65 per share (as of the 2026-11-17 close), against a market price of $4.63. That is a margin of safety of -179.9%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.